Insider Financial icon

Why Intellia Therapeutics Stock Is a “Strong Buy”

Why Intellia Therapeutics Stock Is a “Strong Buy” With Caveats

Apart from artificial intelligence (AI) and cryptocurrency, genome editing research and development has long been a popular stock on Wall Street. Intellia Therapeutics (NASDAQ:NTLA) just earned a critical regulatory green light in this field, propelling Intellia Therapeutics stock higher. Analysts rate the biotechnology firm as a “Strong Buy,” but it still demands extensive due diligence […]

On this website we use first or third-party tools that store small files (cookie) on your device. Cookies are normally used to allow the site to run properly (technical cookies), to generate navigation usage reports (statistics cookies) and to suitable advertise our services/products (profiling cookies). We can directly use technical cookies, but you have the right to choose whether or not to enable statistical and profiling cookies. Enabling these cookies, you help us to offer you a better experience.